JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 114 filers reported holding JOUNCE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.78 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $166,870 | -37.5% | 90,200 | +182.3% | 0.01% | -33.3% |
| Q4 2021 | $267,000 | +12.7% | 31,952 | 0.0% | 0.01% | +12.5% |
| Q3 2021 | $237,000 | +9.2% | 31,952 | 0.0% | 0.01% | +14.3% |
| Q2 2021 | $217,000 | +27.6% | 31,952 | +93.0% | 0.01% | +16.7% |
| Q1 2021 | $170,000 | +56.0% | 16,552 | +6.4% | 0.01% | +20.0% |
| Q4 2020 | $109,000 | -9.2% | 15,552 | +6.1% | 0.01% | -16.7% |
| Q3 2020 | $120,000 | +18.8% | 14,652 | 0.0% | 0.01% | 0.0% |
| Q2 2020 | $101,000 | +44.3% | 14,652 | 0.0% | 0.01% | +20.0% |
| Q1 2020 | $70,000 | -45.3% | 14,652 | 0.0% | 0.01% | -28.6% |
| Q4 2019 | $128,000 | +68.4% | 14,652 | -35.7% | 0.01% | +40.0% |
| Q3 2019 | $76,000 | -32.7% | 22,800 | 0.0% | 0.01% | -28.6% |
| Q2 2019 | $113,000 | +22.8% | 22,800 | +54.1% | 0.01% | +16.7% |
| Q1 2019 | $92,000 | – | 14,800 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 1,347,829 | $9,152,000 | 93.42% |
| Ally Bridge Group (NY) LLC | 550,000 | $3,735,000 | 2.77% |
| ACUTA CAPITAL PARTNERS, LLC | 813,500 | $5,524,000 | 2.58% |
| TRV GP III, LLC | 1,148,780 | $7,800,000 | 2.12% |
| Deep Track Capital, LP | 4,259,653 | $28,923,000 | 1.86% |
| Logos Global Management LP | 1,400,000 | $9,506,000 | 1.23% |
| PFM Health Sciences, LP | 3,972,868 | $26,976,000 | 1.01% |
| Sofinnova Investments, Inc. | 1,481,219 | $10,057,000 | 0.76% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 248,347 | $1,686,000 | 0.70% |
| RTW INVESTMENTS, LP | 4,680,412 | $31,780,000 | 0.66% |